• 1
    Shakespeare W. King Lear. 1605–1606; Act V: Scene 3.
  • 2
    Asrani SK, Wiesner R, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: The 2000–2003 Phase II prospective randomized trial. Am J Transplant 2014; 14: 356366.
  • 3
    De Simone P, Beckebaum S, Koneru B, Fung J, Saliba F. Everolimus with reduced tacrolimus in liver transplantation. Am J Transplant 2013; 13: 13731374.
  • 4
    Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. Am J Transplant 2013; 13: 17341745.
  • 5
    Tumber MB, Dickersin K. Publication of clinical trials: Accountability and accessibility. J Intern Med 2004; 256: 271283.
  • 6
    McKenna G, Sanchez EQ, Khan T, et al. Sirolimus and hepatic artery complications: Reassessing the black box warning. Am J Transplant 2008; 8: 306.
  • 7
    Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.